After 2-year Delay, 2nd Patient Dosed in FLT190 Gene Therapy Trial

After 2-year Delay, 2nd Patient Dosed in FLT190 Gene Therapy Trial

297773

After 2-year Delay, 2nd Patient Dosed in FLT190 Gene Therapy Trial

Almost two years after dosing its first participant, a Phase 1/2 clinical trial testing the gene therapy candidate FLT190 for Fabry disease has treated its second patient. The trial, dubbed MARVEL-1 (NCT04040049), originally had been slated for completion this past March, but had been significantly impacted by the pandemic. “Easing of COVID-19 restrictions, together with geographic expansion of study sites, should enable continued enrollment as we work to make FLT190 available to the Fabry disease…

You must be logged in to read/download the full post.